a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10622982		
Filing Date		2003-07-17		
First Named Inventor	CHAN	4		
Art Unit		2131		
Examiner Name WAN		G		
Attorney Docket Number		4366-124		

		Remove				
		Kind Code1 Issue Date Name of Patentee or Applicant of cited Document		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	
	1	6032258		2000-02-00	Godoroja et al.	
	2	6097703		2000-08-00	Larsen et al.	
	3 6345298 2002-02		2002-02-00	Reed et al.		
	4	6678361		2004-01-00	Rooke et al.	
	5	5958006		1999-09-00	Eggleston et al.	
	6	6118856		2000-09-00	Paarsmarkt et al.	
	7	6442600		2002-08-00	Anderson	
	8	5905777		1999-05-00	Foladare et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10622982	
Filing Date		2003-07-17	
First Named Inventor	CHAN		
Art Unit		2131	
Examiner Name	WANG		
Attorney Docket Number		4366-124	

	9	68540	007		2005-02	-00	Hammond					
If you wis	If you wish to add additional U.S. Patent citation information please click the Add button. Add											
				U.S.P	ATENT	APPLI	CATION PUBL	ICATIONS		Remove		
Examiner Cite Publication Number Kind Codes Date Name of Patentee or Applicant Relevant Reseasor Rel												
	1											
If you wis	h to a	dd add	itional U.S. Publ	shed Ap				lease click the Ad	d buttor	=		
					FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Forei Numi	gn Document ber ³	Country Code ²		Kind Code4	Publication Date	ion Applicant of cited Pa			lumns,Lines levant or Relevant opear	тя
	1											
If you wis	h to a	dd add	itional Foreign F	atent Do	cument	citation	information pl	ease click the Add	button	Add		
				NON	(-PATE)	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country where published.									T 5			
	1											
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add											
EXAMINER SIGNATURE												
Examiner	Signa	ture						Date Consid	ered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10622982	
	Filing Date		2003-07-17	
	First Named Inventor CHAN		4	
	Art Unit		2131	
	Examiner Name WAN		4G	
	Attorney Docket Numb	er	4366-124	

See Kind Code of USPTO Peter Documents at invest, ISETIC GOV or MEPF 961.04. It better dots that issued the document, by the lockletic code (WIPO Standard S13.) If the planeses paint of counters, the includation of the parent for the grant or the representation process the sensal number of the pather comment. If which of counters by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark then if English Intraquate Petersiation as attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10622982		
Filing Date		2003-07-17		
First Named Inventor	CHAN			
Art Unit		2131		
Examiner Name	WANG			
Attorney Docket Number		4366-124		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.98 to make the a	ppropriate selection(s):
---------------	--------------	--------------------	--------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jason H. Vick/	Date (YYYY-MM-DD)	2007-01-16
Name/Print	Jason H. Vick	Registration Number	45285

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleatert and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.